A role of Nrf2 in both immuno- and targeted therapy resistance has been documented; specifically, regarding immunotherapy, Nrf2 may modulate the innate immune responses, mainly in advanced stages of melanoma, suppressing the pro-inflammatory mediators’ expression through the activation of antioxidant genes [157]. Here, NFE2L2 is linked to melanoma.